We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. BOSTON — At 3 years, the Amplatzer Amulet device ...
Please provide your email address to receive an email when new articles are posted on . In a head-to-head comparison of two left atrial appendage closure devices for patients with atrial fibrillation, ...
ABBOTT PARK, Ill., Aug. 30, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data from the Amulet™ LAA Occluder IDE trial, a multi-center, head-to-head study comparing the company ...
BOSTON, MA—For patients with atrial fibrillation who are undergoing left atrial appendage occlusion (LAAO), the Amplatzer Amulet (Abbott) and the first-generation Watchman 2.5 (Boston Scientific) ...
SAN FRANCISCO -- Two mainstream devices for percutaneous left atrial appendage (LAA) closure continued to lead to similar clinical outcomes in the SWISS-APERO trial. Among patients randomized to the ...
WASHINGTON, DC—In initial commercial experiences, both the Watchman and Amplatzer Amulet left atrial appendage (LAA) closure devices were be implanted with high rates of success and low risks of ...
AbbottABT recently announced results for its AMPLATZER Amulet left atrial appendage (LAA) occlusion device in a bid to fortify its core Structural Heart business. Data was presented at EuroPCR, the ...
New Guidelines Issued for Management of Atrial Fibrillation The Amulet device is designed for complete immediate closure of the left atrial appendage using dual-seal technology. Using dual-seal ...
First and only steerable delivery system designed to help seal the left atrial appendage (LAA) in people with atrial fibrillation who are at an increased risk of stroke Now available in the U.S., ...
The Amplatzer Amulet (Abbott) and first-generation Watchman 2.5 (Boston Scientific) devices provide relatively comparable results out to 3 years after left atrial appendage occlusion (LAAO), longer ...
Sophia Antipolis, France – 30 Aug 2021: The Amplatzer Amulet Left Atrial Appendage Occluder has shown superior left atrial appendage (LAA) closure and noninferior safety and effectiveness for stroke ...
SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback